Osteoprotegerin/Fc Chimera from mouse

Description

• General description: Osteoprotegerin (OPG) is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor κ-B ligand) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand).[1][2] The primary structure of OPG protein consists of seven distinct domains, four of which corresponds to the extracellular cysteine-rich domains of TNFR proteins and constitutes the soluble OPG. OPG is expressed in a wide variety of tissues including adult heart, lung, kidney and liver. It is secreted both as a monomeric and a dimeric protein.[3]
• Biochem/physiol Actions: Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, thereby leading to excess accumulation of bone and cartilage.[1] Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders.[2] It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma.[4] OPG plays a vital role in bone metabolism and is involved in inhibition of ovariectomy-associated bone loss in rats.[3][4]
• Physical form: Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline.
• Analysis Note: The biological activity is measured by its ability to neutralize apoptosis of mouse L-929 cells treated with 50 ng/ml recombinant human TRAIL.